PTEN and neoplasm: More recently, another retrospective analysis conducted on 42 patients with mCRC receiving bevacizumab-containing combinations in a first- or second-line treatment showed that a loss of PTEN protein expression in secondary tumor tissue samples was significantly associated with the treatment response (p = 0.02; p-value adjusted for prognostic factors = 0.006) [36].